GlassScriptPhysician profile
Sherene Good
NPI 1437632676
$1,281.27
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $541 · 2022: $740.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $317.93 | 2021-2022 | |
| Novo Nordisk INC | $216.51 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $170.79 | 2021-2022 | |
| Lilly USA, LLC | $141.58 | 2021-2022 | |
| Abbott Laboratories | $128.12 | 2021 | |
| Xeris Pharmaceuticals, INC. | $71.79 | 2022 | |
| Abbvie INC. | $53.53 | 2021-2022 | |
| Radius Health, INC. | $40.34 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.06 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $31.89 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $26.46 | 2022 | |
| Amneal Pharmaceuticals LLC | $18.68 | 2022 | |
| Antares Pharma, INC. | $15.88 | 2021 | |
| Recordati_rare_diseases_inc. | $10.71 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherene Good listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.